Champions Oncology Stock Alpha and Beta Analysis
| CSBR Stock | USD 4.31 0.02 0.46% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Champions Oncology. It also helps investors analyze the systematic and unsystematic risks associated with investing in Champions Oncology over a specified time horizon. Remember, high Champions Oncology's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Champions Oncology's market risk premium analysis include:
Beta 1.15 | Alpha (0.19) | Risk 4.47 | Sharpe Ratio 0.0342 | Expected Return 0.15 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Champions |
Champions Oncology Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Champions Oncology market risk premium is the additional return an investor will receive from holding Champions Oncology long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Champions Oncology. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Champions Oncology's performance over market.| α | -0.19 | β | 1.15 |
Champions Oncology expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Champions Oncology's Buy-and-hold return. Our buy-and-hold chart shows how Champions Oncology performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Champions Oncology Market Price Analysis
Market price analysis indicators help investors to evaluate how Champions Oncology stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Champions Oncology shares will generate the highest return on investment. By understating and applying Champions Oncology stock market price indicators, traders can identify Champions Oncology position entry and exit signals to maximize returns.
Champions Oncology Return and Market Media
The median price of Champions Oncology for the period between Sat, Aug 31, 2024 and Fri, Nov 29, 2024 is 4.47 with a coefficient of variation of 6.32. The daily time series for the period is distributed with a sample standard deviation of 0.28, arithmetic mean of 4.43, and mean deviation of 0.23. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Champions Oncology Reports Quarterly Revenue of 14.1 Million Adjusted EBITDA of 2.0 Million | 09/11/2024 |
2 | Earnings call Champions Oncology reports positive momentum in Q1 FY2025 | 09/12/2024 |
3 | Champions Oncology First Quarter 2025 Earnings EPS US0.097 | 09/13/2024 |
4 | Acquisition by Brady Davis of 135000 shares of Champions Oncology at 6.5 subject to Rule 16b-3 | 09/18/2024 |
5 | Disposition of 8333 shares by Sidransky David of Champions Oncology at 3.21 subject to Rule 16b-3 | 09/23/2024 |
6 | Champions Oncology Is In A Strong Position To Grow Its Business | 09/24/2024 |
7 | Acquisition by Brady Davis of 68000 shares of Champions Oncology at 6.5 subject to Rule 16b-3 | 10/04/2024 |
8 | Champions Oncology Inc Q4 2024 Earnings Call Highlights Navigating Challenges and ... | 10/09/2024 |
9 | Acquisition by Ackerman Joel of 124232 shares of Champions Oncology at 5.76 subject to Rule 16b-3 | 10/11/2024 |
10 | Disposition of 88470 shares by Ackerman Joel of Champions Oncology at 2.1 subject to Rule 16b-3 | 10/31/2024 |
11 | Acquisition by Ackerman Joel of 43190 shares of Champions Oncology at 4.64 subject to Rule 16b-3 | 11/12/2024 |
12 | Acquisition by Breitfeld Philip P. of 8333 shares of Champions Oncology at 11.96 subject to Rule 16b-3 | 11/22/2024 |
About Champions Oncology Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Champions or other stocks. Alpha measures the amount that position in Champions Oncology has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 (projected) | Dividend Yield | 0.003734 | 0.003319 | Price To Sales Ratio | 1.31 | 1.24 |
Champions Oncology Upcoming Company Events
As portrayed in its financial statements, the presentation of Champions Oncology's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Champions Oncology's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Champions Oncology's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Champions Oncology. Please utilize our Beneish M Score to check the likelihood of Champions Oncology's management manipulating its earnings.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 22nd of July 2024 Next Financial Report | View | |
| 31st of January 2024 Next Fiscal Quarter End | View | |
| 22nd of July 2024 Next Fiscal Year End | View | |
| 31st of October 2023 Last Quarter Report | View | |
| 30th of April 2023 Last Financial Announcement | View |
Build Portfolio with Champions Oncology
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Champions Stock Analysis
When running Champions Oncology's price analysis, check to measure Champions Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Champions Oncology is operating at the current time. Most of Champions Oncology's value examination focuses on studying past and present price action to predict the probability of Champions Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Champions Oncology's price. Additionally, you may evaluate how the addition of Champions Oncology to your portfolios can decrease your overall portfolio volatility.